Edition:
India

Uniqure NV (QURE.OQ)

QURE.OQ on NASDAQ Stock Exchange Global Select Market

17.44USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$17.44
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
138,752
52-wk High
$21.35
52-wk Low
$4.74

Select another date:

Wed, Nov 1 2017

BRIEF-Uniqure Q3 loss per share $0.40

* Uniqure announces third quarter 2017 financial results and recent company progress

BRIEF-UniQure reports Q3 loss $0.40/shr

* UniQure announces third quarter 2017 financial results and recent company progress

BRIEF-Uniqure announces proposed public offering

* Uniqure NV - ‍ commenced an underwritten public offering of 5 million of its ordinary shares Source text for Eikon: Further company coverage:

BRIEF-uniQure acquires patent family providing broad protection of hyperactive padua variant of factor IX

* uniQure strengthens intellectual property portfolio with acquisition of patent family providing broad protection of the hyperactive padua variant of factor ix (FIX-padua) Source text for Eikon: Further company coverage:

BRIEF-Uniqure announces AMT-061 to enter pivotal study in 2018

* Uniqure announces Hemophilia B gene therapy program to enter pivotal study with FIX-Padua variant in 2018

BRIEF-Uniqure announces FDA orphan drug designation for AMT-130 in huntington’s disease

* Uniqure announces FDA orphan drug designation for AMT-130 in huntington’s disease Source text for Eikon: Further company coverage:

BRIEF-Uniqure NV Q2 revenue $4.9 million

* Uniqure announces second quarter 2017 financial results and recent company progress

BRIEF-Uniqure NV - ‍Scott Mcmillan named chief operating officer

* Uniqure announces leadership team appointments and nominations to its board of directors

BRIEF-Uniqure reacquires development and commercialization rights for gene therapy candidate in Hemophilia B

* Uniqure reacquires development and commercialization rights for its gene therapy candidate in Hemophilia B

BRIEF-uniQure reacquires development and commercialization rights for its gene therapy candidate in hemophilia B

* uniQure reacquires development and commercialization rights for its gene therapy candidate in hemophilia B

Select another date: